Blph stock zacks
28 Aug 2018 Bellerophon Therapeutics, Inc. (BLPH) could be a stock to avoid from a technical perspective. Find the latest Bellerophon Therapeutics, Inc. (BLPH) stock quote, history, news and other vital information to help you with your stock Zacks•29 days ago BLPH Bellerophon Therapeutics, Inc. daily Stock Chart BLPH: Zacks SCR Initiates Coverage of Bellerophon Therapeutics. Zacks Small Cap Research. Ceragon Networks (CRNT) Needham analyst Alex Henderson assigned a Buy rating to Ceragon Networks today and set a price target of. a month ago - Zacks The split for BLPH took place on February 10, 2020. This was a 1 for 15 reverse split, meaning for each 15 shares of BLPH owned pre-split, the shareholder now View information about BLPH with charts, fundamental and technical data together 2019-12-17 08:44:00 | Bellerophon stock is up 35% on hypertension trial data 2019-08-06 20:15:00 | BLPH: Zacks SCR Initiates Coverage of Bellerophon 6 Aug 2019 Type of Stock. Small-Growth BLPH has several mid-to-late stage clinical studies Zacks Projected EPS Growth Rate - Next 5 Years %. N/A.
BLPH | Bellerophon Therapeutics Inc. Profile | MarketWatch
BLPH Dividend History & Description — Bellerophon Therapeutics Inc. Bellerophon Therapeutics is a clinical-stage therapeutics company focused on developing products for the treatment of cardiopulmonary diseases. Co.'s focus is on the development of its nitric oxide therapy for patients with pulmonary hypertension using its proprietary BLPH Split History Bellerophon Therapeutics (BLPH) has 1 split in our BLPH split history database. The split for BLPH took place on February 10, 2020. This was a 1 for 15 reverse split, meaning for each 15 shares of BLPH owned pre-split, the shareholder now owned 1 share. Analysts Set $35.93 Target Price for Bellerophon ...
It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus
Bellerophon Therapeutics, Inc. Common Stock (BLPH) News ... BBI Awaits Data In Q2, BLPH Breathes Easy, Big Day For BXRX Tomorrow . Feb 18, 2020. Stock Alert: Bellerophon Therapeutics Soars 95% . Jan 28, 2019. Monday 1/28 Insider Buying Report: BLPH, MMLP Bellerophon Therapeutics, Inc. Common Stock (BLPH ... Find the latest Earnings Report Date for Bellerophon Therapeutics, Inc. Common Stock (BLPH) BLPH Bellerophon Therapeutics, Inc. Common Stock. Zacks Investment Research.
Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) have earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Bellerophon Therapeutics market cap history and chart from 2013 to 2019. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Zacks: Analysts Anticipate Bellerophon Therapeutics Inc ... Analysts expect Bellerophon Therapeutics Inc (NASDAQ:BLPH) to announce earnings of ($0.07) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics posted earnings of ($0.20) per share during the same quarter last year, which would suggest a positive year over year growth rate of […] Bellerophon Therapeutics: 1Q Earnings Snapshot May 11, 2020
BLPH: More Clinical Data Supports Utility of INOpulse, Near-Term Value-Inflection Opportunities Grow Zacks Small Cap Research Oct-23-19 12:30PM Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual
BLPH: Bellerophon Therapeutics Inc options chain stock quote. Get the latest options chain stock quote information from Zacks Investment Research. BLPH: Bellerophon Therapeutics Inc price and EPS surprise. Get the latest price and EPS View All Zacks #1 Ranked Stocks. Trades from $1. The Zacks Equity BLPH: Bellerophon Therapeutics Inc industry comparisons. Get the latest stock and industry comparisons from Zacks Investment Research. 28 Aug 2018 Bellerophon Therapeutics, Inc. (BLPH) could be a stock to avoid from a technical perspective. Find the latest Bellerophon Therapeutics, Inc. (BLPH) stock quote, history, news and other vital information to help you with your stock Zacks•29 days ago BLPH Bellerophon Therapeutics, Inc. daily Stock Chart BLPH: Zacks SCR Initiates Coverage of Bellerophon Therapeutics. Zacks Small Cap Research. Ceragon Networks (CRNT) Needham analyst Alex Henderson assigned a Buy rating to Ceragon Networks today and set a price target of. a month ago - Zacks